Actively Recruiting
Randomized Phase 3 Trial Evaluating CKD-843 Safety and Effectiveness in Men with Androgenetic Alopecia
Led by Chong Kun Dang Pharmaceutical · Updated on 2026-09-03
288
Participants Needed
1
Research Sites
39 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are conducting a Phase 3 clinical trial to study the safety and effectiveness of CKD-843 in male patients aged 18 to 50 years with Androgenetic Alopecia, a condition causing hair loss. The study is randomized, double-blind, and parallel-group, comparing CKD-843 with placebo and an active reference drug. The goal is to evaluate how CKD-843 affects hair growth over time. Participants are randomly assigned to one of four groups two different doses of CKD-843 given as intramuscular injections every 3 months, a placebo injection, or daily oral Dutasteride capsules for 12 months. Placebo capsules are also given to some groups to maintain blinding. The study lasts for 12 months of treatment. During the trial, participants will receive their assigned injections and capsules according to schedule and will be regularly assessed for changes in hair count from baseline to 24 weeks. Researchers will monitor safety and treatment effects throughout the 12-month period. The trial is sponsored by Chong Kun Dang Pharmaceutical and aims to provide detailed information on CKD-843s impact on hair growth in men with Androgenetic Alopecia.
CONDITIONS
Brief Title
A Phase 3 Study to Evaluate the Safety and Efficacy of CKD-843 in Male Patients With Androgenetic Alopecia
Research Team
O
OhSang Kwon, MD, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here